



Advent Pharma Limited

Head office: Rupayan Karim Tower,
Level # 10, 80 Kakrail, Ramna, Dhaka-1000, Bangladesh

PRICE SENSITIVE INFORMATION

This is for kind information of all concerned the Board of Directors of Advent Pharma Limited in its Board Meeting held on 14th day of November 2022 at 03.00 pm considered and approved the un-audited Quarterly Financial Statements of the Company for the 1st Quarter (Q1) period from July to September 2022 and took the following price sensitive decisions:

Particulars	July 2022 to September, 2022	July 2021 to September, 2021
Earnings Per Share (EPS)	0.41	0.39
Net Operating Cash Flow (NOCF) per share	0.47	0.43
	As at 30 September 2022	As at 30 June 2022
Net Asset Value (NAV) per share	14.51	14.10

The detail of the Un-Audited Quarterly Financial Statements of the Company for the 1st Quarter (Q1) period from July to September 2022 are also available the web site of the company at www.adventpharmabd.com

By order of the Board

Dated: Dhaka
14 November, 2022

Sd/-
Md. Ikramul Islam
Company Secretary